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Case report
A 50-year-old, otherwise healthy man presented to an 
outside institution with a several-month history of  intermit-
tent abdominal pain. The initial single venous-phase ab-
domen and pelvis CT scan obtained demonstrated an inci-
dental 7-mm enhancing pancreatic tail mass. No other im-
aging findings that could explain his symptoms were identi-
fied. A repeat pancreatic protocol CT study performed at 
our institution 3 months later revealed a mild increase in 
the size of  the enhancing mass lesion to 9 mm. The patient 
denied constitutional symptoms, and laboratory workup 
revealed no abnormalities. Given the interval and the mild 
enlargement, we suspected a nonfunctioning islet cell tumor 
of  the pancreatic tail or a solid pseudopapillary tumor of  
the pancreatic tail. We did not consider the diagnosis of  
IPAS in the differential diagnosis, and we did not perform 
further imaging workup to characterize the lesion and/or 
biopsy. We performed open distal pancreatectomy and 
splenectomy via a left subcostal approach. The patient sub-
sequently developed a subphrenic abscess and an enterocu-
taneous fistula. The abscess was drained, and the enterocu-
taneous fistula healed on conservative management. In 
retrospect, the lesion had similar attenuation values as the 
spleen on the arterial and portal venous phases (Fig. 1, A-
D). The diagnosis of  an IPAS was made on histopathologi-
cal examination of  the surgical specimen (Fig. 2). 
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Accessory spleens are common, usually asymptomatic, incidentally discovered congenital foci of  splenic 
tissue. They occur most commonly near the splenic hilum, with almost 20% in or near the pancreatic 
tail. On contrast-enhanced computed tomography (CT), differentiation of  an intrapancreatic accessory 
splenule (IPAS) from other pancreatic tail lesions such as islet cell tumors and metastatic disease can pre-
sent a diagnostic challenge. A high index of  suspicion on the part of  the radiologist, based on the classic 
location with typical imaging features and a combination of  cross-sectional imaging studies such as ultra-
sound, computed tomography (CT), or magnetic resonance imaging (MRI) with nuclear medicine ex-
aminations, can confirm the diagnosis of  intrapancreatic accessory splenule and prevent unnecessary 
biopsy and/or surgery. 
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Figure 1A. 50-year-old man with intrapancreatic accessory 
spleen. Axial CT scan of the abdomen in the arterial phase 
shows a hypervascular mass (arrow) in the pancreatic tail 
with similar attenuation values as the spleen.
Discussion
Accessory spleens are common, usually asymptomatic, 
incidentally discovered congenital foci of  splenic tissue, 
which are located at variable locations separate from the 
main spleen. They occur most commonly near the splenic 
hilum, with almost 20% in or near the pancreatic tail (1). 
These congenital normal variants carry with them a branch 
of  the splenic artery and drain into the splenic vein (2). 
Accessory spleens can range in size from a few millimeters 
to several centimeters and have been reported to enlarge 
following splenectomy (1). They have been reported to be 
present in 16% of  patients undergoing contrast-enhanced 
abdominal CT scan (3), and as many as 30% of  patients at 
autopsy (4).
Most accessory spleens are readily identified on cross-
sectional imaging by CT or MRI. However, because of  
their relatively hypervascular appearance on contrast-
enhanced CT, differentiation of  an IPAS from other 
pancreatic-tail lesions (islet-cell tumors and metastatic dis-
ease) can present a diagnostic challenge. A high index of  
suspicion by the radiologist, based on the classic location 
near the splenic hilum with typical imaging features and a 
combination of  cross-sectional imaging studies such as ul-
trasound, CT, or MRI with nuclear medicine examinations, 
can confirm the diagnosis of  IPAS and prevent unnecessary 
biopsy and/or surgery (5).
On ultrasound, accessory spleens are seen as round or 
oval structures with echogenecity similar to that of  the 
main spleen; they show posterior acoustic enhancement. A 
high-amplitude interface is observed, due to a fibrotic cap-
sule on histopathology. The presence of  a vascular hilum 
entering the lesion on Doppler ultrasound is a sensitive di-
agnostic feature (2, 6). Contrast-enhanced ultrasound using 
Levovist (Schering, Berlin, Germany) demonstrates en-
hancement patterns similar to the spleen, with dense persis-
tent enhancement for as long as 3 to 5 minutes. This persis-
tent enhancement is related to the entrapment of  Levovist 
by the reticuloendothelial system (RES) cells in the splenic 
tissue, a mechanism similar to that of  Tc-99m heat-
damaged red-blood-cell (HDRBC) scintigraphy and super-
paramagnetic iron-oxide (SPIO)-enhanced MRI (2).
The attenuation of  IPAS on all dynamic CT phases is 
usually similar to that of  the spleen and higher than that of 
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Figure 1B. 50-year-old man with intrapancreatic accessory 
spleen. Axial CT scan of the abdomen in the portal venous 
phase shows the same mass (arrow) in the pancreatic tail 
with similar attenuation values as the spleen.
Figure 1C. 50-year-old man with intrapancreatic accessory 
spleen. Coronal CT reconstruction in the arterial phase 
shows a hypervascular mass (arrow) in the pancreatic tail 
with similar attenuation values as the spleen.
Figure 1D. 50-year-old man with intrapancreatic accessory 
spleen. Sagittal CT reconstruction in the arterial phase 
shows a hypervascular mass (arrow) in the pancreatic tail 
with similar attenuation values as the spleen.
the pancreas. Rarely, an IPAS may have attenuation lower 
than that of  the surrounding pancreas on arterial and por-
tal venous phases when splenic enhancement is delayed, 
such as in cirrhosis (2). A small IPAS can cause a difference 
in the attenuation values relative to the spleen due to partial 
volume effects; using 5-mm or thinner slices may help to 
accurately measure CT attenuation values (3). 
As expected, signal intensities of  IPAS on MRI are iden-
tical to that of  the spleen on multiple pulse sequences with 
dynamic gadolinium enhancement similar to that of  the 
normal spleen. Rarely, an IPAS may be brighter than the 
spleen on T2-weighted images due to higher white-to-red 
pulp ratio. SPIO-enhanced MRI can help confirm the di-
agnosis of  IPAS by loss of  signal intensity, similar to the 
spleen and negative contrast enhancement. It has the ad-
vantage of  better spatial resolution than scintigraphy (2).
Technetium-99m HDRBC scintigraphy is a highly spe-
cific method for detecting splenic tissue, as up to 90% of  
injected HDRBCs are trapped by the splenic tissue. The 
diagnostic criterion for IPAS is the presence of  a marked 
increase in uptake that exceeds that of  the cardiac blood 
pool and the major vessels at the site of  suspected accessory 
spleen. The drawback of  this technique is poor anatomic 
resolution (even when single-photon-emission computed 
tomography (SPECT) is employed) when compared to CT 
and MRI (2). Alternatively, a technetium-99m sulphur col-
loid scan may be performed. No uptake is seen in neuroen-
docrine tumors or metastases using either of  the two 
techniques (5).
It is sometimes difficult to distinguish an IPAS from a 
nonfunctioning islet-cell tumor or hypervascular metastasis 
based on imaging findings alone. On CT and MRI, islet-
cell tumors often demonstrate uniform or ring-like en-
hancement, especially during the early arterial phase. Fur-
thermore, the characteristic arciform or zebra-patterned 
enhancement pattern of  the spleen is not seen in islet-cell 
tumors. On SPIO-enhanced MRI, islet tumors do not show 
loss of  signal intensity or negative enhancement, due to the 
absence of  RES cells. Hematogenous hypervascular metas-
tases to the pancreas are rare and usually manifest in ad-
vanced disease. Melanoma, lung cancer, and breast carci-
noma are the most common origins of  pancreatic metasta-
ses. On CT and MRI, metastases usually demonstrate 
rapid enhancement on the arterial phase, but there is de-
creased lesion conspicuity on the portal venous phase, 
which is diminished even further on the delayed phase. 
Sometimes the distinction between metastasis and IPAS is 
difficult on imaging, and the clinical history is helpful in 
those cases. However, a hypervascular pancreatic tumor in 
the setting of  renal-cell carcinoma should be considered a 
metastasis from renal cancer unless proven otherwise (2).
In conclusion, IPAS is becoming a more easily detectable 
lesion with ever-improving imaging capability. Radiologists 
should be aware of  this entity and have a high index of  
suspicion if  a subtle enhancing pancreatic tail mass is de-
tected on CT. Knowledge of  specific multimodality imag-
ing characteristics using ultrasound, CT, MRI, and nuclear 
medicine examinations can prevent unnecessary biopsy 
and/or surgery. 
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Figure 2. 50-year-old man with intrapancreatic accessory 
spleen. Hematoxylin and eosin stain performed on the sur-
gical specimen shows an accessory spleen with a fibrotic 
capsule (arrows) surrounded by normal pancreatic tissue.
